SCAI to Host Fellows Course at LWSIC 2015 in Chandigarh, India This Weekend
SCAI will be taking its focus on education for early-career interventionalists all the way to Chandigarh, India this weekend as it hosts the SCAI Interventional Cardiology Fellows & Early Career Course Aug. 1-2 as part of LWSIC 2015 & 4th NHFS. Registration for the SCAI Course is open for all fellows and early-career practitioners (DM Cardiology Residents, DNB Cardiology Residents, Interventional Cardiology Fellows and Junior and Assistant Consultants).
Organized by Harinder K. Bali, MD, DM, LWSIC 2015 (Live Workshop and Symposium in Interventional Cardiology) & 4th NHFS (National Heart Failure Summit) focuses on the latest advances and treatment modalities in cardiovascular medicine. In addition to didactic presentations, quizzes and interactive case sessions on various contemporary topics in cardiovascular medicine, the educational agenda also includes a live workshop in which internationally acclaimed interventionists/ electrophysiologists conduct complex coronary, endovascular and device implantation procedures.
"This is a tremendous opportunity for SCAI to engage interventionalists in northern India," said SCAI Trustee Sundeep Mishra, MD, FSCAI, who is serving as SCAI Course Co-Director with Ramesh Daggubati, MD, FSCAI. "Most importantly we are reaching a group that needs it most of all — fellows and early career interventional cardiologists."
In addition to Drs. Mishra and Daggubati, SCAI faculty for the Fellows Course and LWSIC 2015 & 4th Annual NHFS include:
Find out more about LWSIC 2015 & 4th NHFS.
Sameer Gupta, MD
- Luis Guzman, MD, FSCAI
- Saibal Kar, MD, FSCAI
- Ayman Magd, MD, FSCAI
- Mehdi Shisheboor, MD, FSCAI
| Share this article:
Don't Miss SCAI TAVR Session at SOLACI
Attending SOLACI/SOCIME 2015 in Mexico City next week? Then be sure not to miss the SCAI Session on TAVR on Friday, Aug. 7, featuring Mauricio Cohen, MD, FSCAI, Ted Feldman, MD, MSCAI, and Mayra Guerrero, MD, FSCAI. Taking place in the Main Arena at 10:15 a.m., this special session will review the latest clinical trial data and focus on what you need to know for your daily practice. The session will also cover patient selection and choice of access, best practices for device sizing, how to prevent complications and more! Also, be sure not to miss the Best Abstracts Session in collaboration with SCAI and Catheterization & Cardiovascular Interventions from 12:15 p.m. to 1:15 p.m. on Friday.
Download the final program here.
TAVR Center: Catch Up With July Journal Scan and Summer Poll
TAVR is such a fast-evolving therapy, it's tough to keep up with the latest developments. Let the SCAI TAVR Center do the work for you with our monthly journal scans, quarterly polls, case reviews and the latest headlines on the topic.
Catch up with the July Journal Scan, a compilation of the past month's top TAVR-related journal articles assembled by Kreton Mavromatis, MD, FSCAI, and George Hanzel, MD, FSCAI, including the review of this top article in JACC: "2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement."
Also, be sure to weigh in our Summer Poll before it closes. We want to know who you believe TAVR should be offered to given the introduction of the Corevalve Evolut R and the Sapien 3. Participate now at www.SCAI.org/TAVRCenter.
The SCAI TAVR Center is supported through an educational grant from platinum sponsor Medtronic. The Society gratefully acknowledges this support while taking sole responsibility for all content developed and disseminated through this effort.
FDA Approves 1st PCSK9 Inhibitor
The Food and Drug Administration granted approval to alirocumab (Praluent) for heterozygous familial hypercholesterolemia (FH) and for patients with clinical atherosclerotic cardiovascular disease, making it the first in the new class of lipid-lowering PCSK9 inhibitors.
The approval was for use in addition to diet and maximally tolerated statin therapy in adults who require additional LDL cholesterol lowering.
PCSK9 Inhibitors, How Big a Thing?
The cholesterol-lowering drugs known as PCSK9 inhibitors are widely expected to be the next big thing in cardiology. The indications are for patients intolerant or insufficiently responsive to statins, and/or those with specific genetic conditions that lead to ultra-high cholesterol levels. Their effects on cholesterol levels are dramatic, but as yet, there is no proof that these agents improve actual clinical outcomes.
GLIDESHEATH SLENDER® 5Fr and 7Fr!
The only family of unique thin-wall sheaths, offering radial access to more patients.
• Increase Your Radial Access Options
• Optimize Procedural Outcomes
• Preserve Arterial Function
*GLIDESHEATH SLENDER® is currently available in 6Fr.
©2015 Terumo Medical Corporation. All rights reserved.
All brand names are trademarks or registered trademarks of Terumo. TIS-694-06012015
Physicians-in-training Likely to Order Brand-name Statins When Supervisors Prefer Them
Supervising physicians' prescribing of brand-name statins appears to have a significant influence on first-year residents' prescription habits, according to findings published in the Journal of General Internal Medicine. The findings could have implications for training reforms to increase emphasis on cost-effectiveness, Kira L. Ryskina, MD, MS, told Cardiology Today.
Evidence of Plaque Regression Bolsters Case for Combining Ezetimibe With Statin
On the heels of the IMPROVE-IT trial, which supported adding ezetimibe to statin therapy in ACS patients, a new study shows the combination not only has beneficial effects on cholesterol levels in both ACS and stable angina patients but also induces a corresponding regression of coronary plaque. The study was published in the Aug. 4 issue of the Journal of the American College of Cardiology.
Minimal, Maximal Pulmonary Vein Isolation Yield Similar Freedom From AF
Freedom from atrial fibrillation occurred at similar rates between minimal and maximal pulmonary vein isolation strategies, according to results from the MINIMAX study.
However, patients in whom antral isolation can be achieved without intervenous ridge ablation had higher long-term freedom from AF, the researchers wrote.
3 Ways to Cut Unnecessary Readmissions of Heart Patients
Given the Centers for Medicare and Medicaid Services' financial penalties for hospitals with above-average readmission rates, many organizations seek ways to prevent 30-day readmissions of patients who undergo percutaneous coronary intervention, or what's commonly known as angioplasty. It's not uncommon for anxious patients to end up back in the emergency department complaining of chest pain, especially if they can't reach their cardiologists.
Chest Pain, No CCTA-Detected Major CAD Can Allow Early Discharge
Low- to intermediate-risk patients who arrived at a hospital emergency department with chest pain and had a coronary CT angiography scan were discharged in about eight hours if the scan failed to detect significant CAD; otherwise they were discharged after about 3 days, in a single-center study. Dr. Nandini M Meyersohn explained that the emergency department of their tertiary-care center has a CT scanner.
For a complete list of job postings, click here.
To post your resume, click here.
||SCAI Fellows Course at LWSIC
||SCAI TAVR Session @ SOLACI
||Mexico City, MEXICO
||SCAI China Fellows Course
||SCAI CPVI - Complex Peripheral Vascular Interventions
SCAI at Great Wall International Congress of Cardiology
SCAI Fellows Course at AICT 2015
||SCAI 2015 Fall Fellows Courses
||SCAI Session at CardioEgypt 2016
|May 4-7, 2016
||SCAI 2016 Scientific Sessions
CLICK HERE for a full calendar of SCAI events
The news summaries appearing in SCAI This Week are based on original information from news organizations and are produced by Multibriefs, an independent e-mail newsletter publisher. SCAI is not responsible for the content of sites external to SCAI, nor do reports in SCAI This Week constitute the official opinion of SCAI.
The SCAI This Week news roundup is provided as a timely update for SCAI members and other healthcare professionals. Links to articles are provided for readers' convenience and may be of use in discussions with patients or colleagues. Questions and comments about SCAI This Week may be directed to Multibriefs at email@example.com.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063